Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
Finished Drug Prices
NA
1. Symdeko
2. Tezacaftor - Ivacaftor
3. Tezacaftor And Ivacaftor
4. Tezacaftor, Ivacaftor Drug Combination
5. Tezacaftor; Ivacaftor
1. Ivacaftor Regimen With Tezacaftor
2. 1969264-35-4
3. Ivacaftor / Tezacaftor
4. Tezacaftor / Ivacaftor
5. Tezacaftor And Ivacaftor
6. Ivacaftor And Tezacaftor
7. Tezacaftor Mixture With Ivacaftor
8. Dtxsid401027914
9. 3-quinolinecarboxamide, N-(2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-1,4-dihydro-4-oxo-, Mixture With 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-n-(1-((2r)-2,3-dihydroxypropyl)-6-fluoro-2-(2-hydroxy-1,1-dimethylethyl)-1h-indol-5-yl)cyclopropanecarboxamide
Molecular Weight | 913.0 g/mol |
---|---|
Molecular Formula | C50H55F3N4O9 |
Hydrogen Bond Donor Count | 7 |
Hydrogen Bond Acceptor Count | 13 |
Rotatable Bond Count | 12 |
Exact Mass | 912.39211383 g/mol |
Monoisotopic Mass | 912.39211383 g/mol |
Topological Polar Surface Area | 192 Ų |
Heavy Atom Count | 66 |
Formal Charge | 0 |
Complexity | 1530 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (CF) aged 6 years and older who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3AG, S945L, S977F, R1070W, D1152H, 2789+5GA, 3272 26AG, and 3849+10kbCT.
R07AX31
R - Respiratory system
R07 - Other respiratory system products
R07A - Other respiratory system products
R07AX - Other respiratory system products
R07AX31 - Ivacaftor and tezacaftor
https://www.pharmacompass.com/radio-compass-blog/top-drugs-and-pharmaceutical-companies-of-2019-by-revenues
11 Jan 2022
// PHARMATIMES
https://www.pharmatimes.com/news/european_commission_approves_cystic_fibrosis_treatment_for_six_to_11-year-olds_1386105
19 Nov 2021
// BUSINESSWIRE
21 Dec 2020
// BIOSPACE
https://www.biospace.com/article/releases/vertex-announces-fda-approvals-of-trikafta-elexacaftor-tezacaftor-ivacaftor-and-ivacaftor-symdeko-tezacaftor-ivacaftor-and-ivacaftor-and-kalydeco-ivacaftor-for-use-in-people-with-cf-with-certain-rare-mutations/?s=74
01 Dec 2020
// Selina McKee PHARMATIMES
http://www.pharmatimes.com/news/symkevikalydeco_cleared_for_use_in_young_cf_patients_1358460
24 Sep 2020
// BUSINESSWIRE
https://www.businesswire.com/news/home/20200924005175/en/Vertex-to-Present-New-Data-at-European-and-North-American-Virtual-Cystic-Fibrosis-Conferences-Highlighting-Long-Term-Use-of-CFTR-Modulators
23 Sep 2020
// PRESS RELEASE
https://icer-review.org/announcements/icer-issues-final-report-and-policy-recommendations-on-treatments-for-cystic-fibrosis/
Global Sales Information
Company :
Tezacaftor/IVacaftor
Drug Cost (USD) : 13,211,860
Year : 2022
Prescribers : 65
Prescriptions : 501
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Tezacaftor/IVacaftor
Drug Cost (USD) : 13,349,210
Year : 2021
Prescribers : 75
Prescriptions : 535
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?